AB
INZY

Amalgamated Bank’s Inozyme Pharma INZY Stock Holding History

Amalgamated Bank’s Portfolio INZY Stock Details INZY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,676
Closed -$2K – 3069
2025
Q1 		$2K Hold
1,676
– – ﹤0.01% 2846
2024
Q4 		$5K Hold
1,676
– – ﹤0.01% 2730
2024
Q3 		$9K Hold
1,676
– – ﹤0.01% 2497
2024
Q2 		$7K Buy
1,676
+535
+47% +$2.59K ﹤0.01% 2614
2024
Q1 		$9K Sell
1,141
-1,811
-61% -$9.94K ﹤0.01% 2486
2023
Q4 		$13K Sell
2,952
-340
-10% -$1.21K ﹤0.01% 2805
2023
Q3 		$14K Hold
3,292
– – ﹤0.01% 2809
2023
Q2 		$18K Buy
+3,292
New +$19.5K ﹤0.01% 2789
2022
Q2 		– Sell
-1,732
Closed -$7K – 3118
2022
Q1 		$7K Buy
+1,732
New +$10.2K ﹤0.01% 3002

Other funds holding INZY

BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
PBPIA
Pivotal bioVenture Partners Investment Advisor San Francisco, California $280M AUM 181.4% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
OBAM
ODDO BHF Asset Management Paris, France $2.54B AUM 41.83% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Amalgamated Bank's INZY Position: Q2 2025 in Review

Amalgamated Bank sold out of Inozyme Pharma (INZY) in Q2 2025, closing a stake of 1,676 shares — an estimated $2K sold.

Amalgamated Bank first reported a position in INZY in Q1 2022 and held it in 9 quarters. The position peaked at $18K in Q2 2023. 86 funds tracked by Wall St. Rank hold INZY as of Q2 2025.

  • Amalgamated Bank reported no remaining Inozyme Pharma position as of Q2 2025 after selling out during the quarter.
  • Amalgamated Bank sold 1,676 Inozyme Pharma shares in Q2 2025, an estimated $2K.
  • Amalgamated Bank first reported a position in Inozyme Pharma in Q1 2022 and held it in 9 quarters.
  • Amalgamated Bank's Inozyme Pharma position peaked at $18K in Q2 2023.
  • 86 funds tracked by Wall St. Rank held Inozyme Pharma as of Q2 2025.

Based on Amalgamated Bank's 13F filing for Q2 2025, filed 4 Aug 2025.